Tallon focusing MHRA on U.K.’s strengths

The U.K. government will have to find common ground with pharmas on reimbursement if it wants to win the competition for life sciences investments. Fortunately for Lawrence Tallon, the CEO of MHRA, his job, creating a world-class regulatory environment, is less contentious.

Tallon, appointed CEO of MHRA five months ago, described his plans in an interview with BioCentury. ...